INVO Bioscience Reports First Quarter 2020 Financial Results

|May 15|magazine32 min read

SARASOTA, Fla., May 15, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced financial results for the quarter ended March 31, 2020.

Financial Results and Updates

  • Revenue for the quarter ended March 31, 2020 totaled $258,571 compared to $189,432 in Q1 2019, an increase of 36% from the comparable period in 2019. Revenue growth was driven by increased product sales in the U.S. related to the Company's U.S. commercialization partner, Ferring Pharmaceutical, and their ongoing marketing activities.
  • Gross margin for the quarter ended March 31, 2020 was approximately 88% compared to approximately 94% in the quarter ended March 31, 2019.
  • Incurred a net loss of $(1,444,392) during the quarter ended March 31, 2020 compared to a net loss of $(458,570) during the quarter ended March 31, 2019, as a result of increased commercialization efforts, which included non-cash expenses totaling approximately $760,000.
  • The Company finished the quarter ended March 31, 2020 with a cash position of approximately $350,000. On May 15, 2020, the Company consummated a closing of its convertible note and unit purchase option offering, resulting in gross proceeds of $2.1 million.
  • U.S. clinic locations trained to offer INVOcell have nearly tripled since our agreement with Ferring International Center, S.A. ("Ferring").  Ferring has established a website, www.invocell.com, which provides information for patients and health care professionals, in addition to providing a tool to search for clinic locations that offer INVOcell.
  • The Company's ticker symbol was changed to "INVO" to align our public market trading symbol with our corporate name and our innovative fertility solution to improve the consistency of our branding along with our overall recognition within the investment community.

Management Discussion

"Although the industry has been impacted by COVID-19 and the cadence in product ordering activity has been affected, we believe our annual goals remain achievable with a shift to the second half of the year.  We also continue to advance a number of key initiatives aimed at increasing the adoption of INVOcell in the U.S. and around the world," commented Steve Shum, Chief Executive Officer of INVO Bioscience. "One critical advancement over the past few weeks was the April 2020 publishing of outcomes data by the Society for Assisted Reproductive Technology, or SART, which reflected increased usage of INVOcell (IVC) and clinical pregnancy success rates for 5-day incubation. We are pleased to see the increased adoption along with the further validation of the overall success rates using our technology.  We also continue to ramp our commercialization efforts with the appointment of highly successful industry professionals covering key geographies and functions, which we believe will help to expand our international opportunities."

Recently Published 2018 Society for Assisted Reproductive Technology ("SART") Data*

The Society for Assisted Reproductive Technology ("SART") recently published the 2018 outcomes data in April 2020, which reflected increased usage of INVOcell and 5-day incubation results.  This Retrospect data reflected an approximate 52% clinical pregnancy success rate for day-5 transfers, comparable to the 2017 data published last year.

Total SART Data 2017-2018 Day 5 IVC*

SART IVC 5-Day TOTAL (2017 + 2018)

< 35

35 - 37

38 - 40

41 - 42

> 42

Total

Rate

Cycles (Fresh + Frozen)

361

114

63

17

2

557


Clinical pregnancies

198

55

29

5

1

288

51.7%

Live birth per transfer

156

45

23

4

1

229

41.1%

*INVO incubation period is country specific and is indicated for 3-5 days.  In the US, the INVOcell Culture Device and Retention Device is not indicated for incubation periods exceeding 72 hours.  FDA has not approved or cleared the product as safe and effective for use for incubation periods exceeding 72 hours (off-label).  The Company has not studied the safety or efficacy of the device for incubation periods exceeding 72 hours and potential risks of off-label use is unknown.  Reference US Instructions for Use (IFU) at https://www.invocell.com/hcp/wp-content/uploads/sites/6/2019/04/INVOcell-Instructions-For-Use-Booklet_R9-1.pdf.

International Market Update

  • Africa and Eurasia: The Company previously executed distribution agreements in certain markets in Africa and Eurasia toward the end of 2019.  Following execution of those agreements, the Company began the product registration and approval process in order to begin importing into those markets. While each market can vary in the time needed to complete such registrations, (from a few months to 6 months or more, depending on the market) these timelines were also impacted by COVID-19.  The Company believes it is close to completing those registrations and expects to be in a position to begin delivering INVOcell to the respective partners or distributors in the second half of 2020. 
  • India: INVO Biosciences' JV partnership, signed in January 2020, is making progress toward opening the first dedicated INVO-only clinic. While there was an impact due to the pandemic, the Company believes the first clinic will come online before year end.
  • New Markets: INVO Bioscience is targeting a number of additional markets and has discussions underway in Canada, Mexico, Columbia, Spain, Macedonia, Taiwan, Malaysia, and China among others.  The Company has set a goal of adding additional OUS markets (through distribution or partnerships) before year end.

Recent Key Appointments

  • We appointed Christopher A. Myer as The Company's Vice President Business Development – Americas in March 2020  to direct the Company's initiative to develop the INVO clinic business in the United States and Canada, develop commercialization agreements in Mexico, as well as Central and South America, and develop cost savings analysis models for third-party payors and governments to highlight the benefits of the INVOcell solution.
  • Appointed Inger Britt Carlsson, PhD, as the Company's Vice President of Medical Affairs in January 2020. Dr. Carlsson will be developing and overseeing INVO Bioscience's educational symposiums, generating scientific abstracts/publications on the INVOcell technology, and building relationships with key opinion leaders around the world.
  • Appointed Yve Lyppens as Director Business Development Asia Pacific in March 2020.  Based in Hong Kong, Mr. Lyppens will be responsible for developing the Company's sales and distribution network throughout Asia.

Financial Results

Revenue for the period ended March 31, 2020 was $258,571 compared to $189,432 for the same period a year ago. The increase was the result of product sales to Ferring as well as from recognizing $178,572 of the Ferring seven-year U.S. exclusive licensing & distribution fee.

Gross margin reported for the period ended March 31, 2020 was approximately 88% or $228,577 compared to 94% or $178,454 for March 31, 2019. The decrease in gross margin relates primarily to a heavier mix of product sales versus the amortization of the up-front license payment which has zero cost of goods.

Operating expenses totaled $1,625,096 in the first quarter of 2020 compared to $527,565 in the same period a year ago. The increase in expenses was primarily the result of an increase in wages, professional fees, legal fees, and clinical support services.  A substantial portion of the increase, or approximately $680,000, relates to non-cash charges associated with stock and option expensing, a portion of which was a one-time impact.  The actual cash expense increase was consistent with the Company's plan to increase its product commercialization efforts as well as its clinical activities related to the 5-day label enhancement.

The net loss for the three months ended March 31, 2020 was $(1,444,392) as compared to a net loss of $(458,570) for the same three-month period in 2019.

The Company finished the quarter ended March 31, 2020 with a cash position of approximately $350,000. On May 15, 2020, the Company consummated a closing of its convertible note and unit purchase option offering, resulting in gross proceeds of $2.1 million (of which $1,961,360 was received in cash and $143,640 resulted from cancellation of indebtedness) before fees and commissions. The Company plans to use proceeds from the transaction to fund its operating plan and believe this convertible note and unit purchase option financing moves the company closer to its objective of uplisting its stock to a senior stock exchange, which could enhance visibility of the Company in the public markets.

Virtual Investor Conference Details

INVO Bioscience is scheduled to participate in a virtual presentation and fireside chat at the May 2020 Lytham Partners Virtual Investor Conference on Wednesday, May 20, 2020 at 2:00pm ET (11:00am PT).

A webcast of the presentation will be posted under the investor relations section of INVO Bioscience's website at www.invobioscience.com  or can be accessed at https://www.webcaster4.com/Webcast/Page/2162/34792.  A replay of the presentation will be available following the event.

Management will also be participating in virtual one-on-one meetings on May 21, 2020. To arrange a meeting, please contact Robert Blum of Lytham Partners at [email protected] or visit www.lythampartners.com/virtual.

About INVO Bioscience

We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

 

  

INVO BIOSCIENCE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)










For the



For the




Three Months



Three Months




Ended



Ended




March 31,



March 31,




2020



2019




















Revenue









Product Revenue


$

80,000



$

10,860


License Revenue



178,571




178,572




















Total Revenue



258,571




189,432











Cost of Goods Sold:



29,994




10,978











Gross Margin



228,577




178,454




















Selling, general and administrative expenses



1,595,046




527,565


Research and developments costs



30,050




-


      Total operating expenses



1,625,096




527,565











Loss from operations



(1,396,519)




(349,111)











Other (income) expense:









Interest expense



47,873




109,459


 Total other (income) expenses



47,873




109,459











Loss before income taxes



(1,444,392)




(458,570)











Provisions for income taxes



-




-











Net Loss


$

(1,444,392)



$

(458,570)











Basic net loss per weighted average shares of common stock


$

(0.01)



$

(0.00)











Diluted net loss per weighted average shares of common stock


$

(0.01)



$

(0.00)











Basic weighted average number of shares of common stock



157,375,918




154,102,856











Diluted weighted average number of shares of common stock



157,375,918




154,102,856


 

 

INVO BIOSCIENCE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS










March 31,



December 31,




2020



2019


ASSETS


(unaudited)






Current assets









    Cash


$

350,000



$

1,238,585


    Accounts receivable net



3,699




7,558


    Inventory, net



162,283




101,387


    Prepaid expense and other current assets



173,235




195,910


      Total current assets



689,217




1,543,440











Property and equipment, net



111,055




93,055











Other Assets:









Capitalized patents, net



6,782




7,234


Lease right of use, net



96,354




101,883


Trademarks



54,474




49,867


Total other assets



157,610




158,984











Total assets


$

957,882



$

1,795,479











LIABILITIES AND STOCKHOLDERS' DEFICIENCY









Current liabilities









     Accounts payable and accrued liabilities, including related parties


$

294,739



$

371,530


     Accrued compensation



487,161




393,017


     Deferred revenue



714,286




714,286


     Current portion of lease liability



21,704




21,365


     Convertible notes, net of discount



371,695




-


     Convertible notes, net of discount – related party



33,152




-


     Income taxes payable



912




912


          Total current liabilities



1,923,649




1,501,110











Commitments and contingencies



-




-











Lease liability, net of current portion



75,992




81,494


Deferred revenue



3,392,857




3,571,429


Convertible notes, net of discount



-




325,784


Convertible notes, net of discount – related party



-




28,824


Deferred tax liability



433




433











Total liabilities



5,392,931




5,509,074











Stockholder's deficiency









Preferred Stock, $.0001 par value; 100,000,000 shares authorized;
   No shares issued and outstanding as of March 31, 2020 and December 31,
      2019, respectively



-




-


Common Stock, $.0001 par value; 200,000,000 shares authorized;
   157,774,336 and 156,316,112 issued and outstanding as of March 31, 2020
      and December 31, 2019, respectively



15,777




15,631


   Additional paid-in capital



20,882,332




20,159,540


   Accumulated deficit



(25,333,158)




(23,888,766)


      Total stockholder's deficiency



(4,435,049)




(3,713,595)











Total liabilities and stockholders' deficiency


$

957,882



$

1,795,479


 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/invo-bioscience-reports-first-quarter-2020-financial-results-301060342.html

SOURCE INVO Bioscience, Inc.